Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1255-1260

  Morito, Toshiaki ^a   Fujihara, Megumu ^b   Asaoku, Hideki ^b   Tari, Akira ^b   Sato, Yasuharu ^a   Ichimura, Kouichi ^a   Tanaka, Takehiro ^a   Takata, Katsuyoshi ^a   Tamura, Maiko ^a   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; LACTATE DEHYDROGENASE; PROTEIN P53; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; SURVIVAL ANALYSIS;

EID: 67449095167     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01167.x     Document Type: Article

References (28)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
3. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
4. Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001; 66: 24-30.
5. Goto H, Tsurumi H, Takemura M et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005; 131: 73-9.
6. Oki Y, Kato H, Matsuo K et al. Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 2008; 49: 1345-51.
7. Rubin LA, Kurman CC, Fritz ME et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-7.
8. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990; 113: 619-27.
9. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
10. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-6.
11. Muris J, Meijer C, Vos W et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714-23.
12. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
13. Fu K, Weisenburger DD, Choi WW et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-94.
14. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-94.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-81.
16. Cox D. Regression models and life-tables. J R Stat Soc 1972; 34: 187-202.
17. Rubin LA, Snow KM, Kurman CC, Nelson DL, Keystone EC. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: Correlations with disease activity. J Rheumatol 1990; 17: 597-602.
18. Hurteau JA, Woolas RP, Jacobs IJ et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 1995; 76: 1615-20.
19. Shiozawa E, Yamochi-Onizuka T, Takimoto M, Ota H. The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leukemia Res 2007; 31: 1579-83.
20. Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-20.
21. van Imhoff GW, Boerma EJ, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-42.
22. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-70.
23. Saito B, Shiozawa E, Usui T et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007; 21: 2563-6.
24. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP. A prospective correlative study. Blood 2006; 107: 4207-13.
25. Costa LJ, Feldman AL, Micallef IN et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 404-12.
26. + diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients. Haematologica 2008; 93: 1195-202.
27. Ennishi D, Takeuchi K, Yokoyama M et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-6.
28. Chang CC, Liu YC, Cleveland RP, Perkins SL. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 2000; 113: 512-8.